BMC Neurology最新文献

{"title":"The role of immune cell phenotypes and metabolites in the risk of ischemic stroke: a Mendelian randomization-based mediation analysis.","authors":"Qiming Liu, Rui Shi, Yiting Gu, Jiayun Zhang, Shiduo Wang, Tiantian Xu, Zhe Zhang, Junbiao Tian","doi":"10.1186/s12883-025-04205-5","DOIUrl":"https://doi.org/10.1186/s12883-025-04205-5","url":null,"abstract":"<p><strong>Background: </strong>Ischemic stroke (IS) occurs when a blood clot obstructs a blood vessel supplying blood to the brain, leading to brain tissue damage due to insufficient oxygen and nutrients. The roles of immune cells and metabolites in IS are increasingly recognized, yet their specific mechanisms remain unclear.</p><p><strong>Methods: </strong>This study conducted a comprehensive statistical analysis to explore the relationships between immune cell phenotypes, metabolite levels, and IS. We utilized methods such as inverse variance weighted (IVW), weighted median, and MR Egger to ensure robust results. Sensitivity analyses were performed to confirm the absence of significant heterogeneity or pleiotropy.</p><p><strong>Results: </strong>We identified several immune cell phenotypes significantly associated with IS. Notably, IgD + CD24 + AC showed a positive association with IS (OR = 1.045601, p = 0.011562), while CD62L- HLA DR + + monocyte AC demonstrated a negative association (OR = 0.948673, p = 0.005415). Among metabolites, adenosine 5'-monophosphate (AMP) to cysteine ratio was positively associated with IS (OR = 1.083144, p = 0.000310), whereas xanthurenate levels were negatively associated (OR = 0.926100, p = 0.001614). Mediation analysis revealed a significant mediating effect of acetylcarnitine levels on the relationship between IgD + CD24 + AC and IS, with an estimated mediation effect of 0.00606 (p = 0.036834077).</p><p><strong>Conclusion: </strong>Our study highlights the crucial roles of specific immune cell phenotypes and metabolites in IS, suggesting their potential as novel therapeutic targets or biomarkers. The mediation analysis underscores the complex interactions between immune cells and metabolites in IS, providing valuable insights for future research. These findings pave the way for further exploration of the pathophysiological mechanisms and therapeutic strategies for IS.</p>","PeriodicalId":9170,"journal":{"name":"BMC Neurology","volume":"25 1","pages":"196"},"PeriodicalIF":2.2,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12054204/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Safety and Efficacy of 156 U - 195 U OnabotulinumtoxinA in Adults With Chronic Migraine: Results From the REPOSE Study.","authors":"Fayyaz Ahmed, Charly Gaul, Katja Kollewe, Ritu C Singh, Katherine Sommer","doi":"10.1186/s12883-025-04087-7","DOIUrl":"https://doi.org/10.1186/s12883-025-04087-7","url":null,"abstract":"<p><strong>Background: </strong>The phase 3 PREEMPT clinical trials confirmed the efficacy and safety of 155 U - 195 U onabotulinumtoxinA for individuals with chronic migraine (CM) and is the licensed dose in Canada and Europe. This analysis aimed to analyze the efficacy and safety parameters of 155 U - 195 U onabotulinumtoxinA in participants with CM from the real-world REPOSE study.</p><p><strong>Methods: </strong>REPOSE (NCT01686581) was a 2-year, prospective, observational, noninterventional, open-label study that described the real-world use of onabotulinumtoxinA in adults with CM in Europe. Participants received onabotulinumtoxinA approximately every 12 weeks and were monitored for 24 months after starting treatment. Data on participant-estimated mean headache-day frequency in the last month (MHD), Migraine-Specific Quality of Life Questionnaire (MSQ) scores, and adverse events (AEs) were collected at each treatment visit. Participants in the safety analysis population (those who received at least one dose of onabotulinumtoxinA) were stratified into two groups based on the dosage received at four or more treatment visits: 155 U onabotulinumtoxinA and 156 U - 195 U onabotulinumtoxinA groups.</p><p><strong>Results: </strong>A total of 641 participants were enrolled at 77 centers. Of those, 218 participants received 155 U ≥ 4 treatment visits, and 77 participants received 156 U-195 U onabotulinumtoxinA ≥ 4 treatment visits. Between-group baseline characteristics were similar. Reductions from baseline in MHD frequency were observed at both doses (156 U - 195 U range, -8.7 to -14.2 MHDs; 155 U range, -8.2 to -11.9 MHDs). Mean change from baseline in MSQ domain scores improved across administration visits for both 155 U onabotulinumtoxinA and 156 U - 195 U onabotulinumtoxinA groups. Treatment with 156 U - 195 U onabotulinumtoxinA was safe and generally well-tolerated with no new safety signals identified. Adverse drug reactions (ADR) were reported in 51/218 in the 155 U group and 10/77 participants in the 156 U - 195 U group; serious adverse drug reactions were 3/218 and 1/77, respectively. The most frequently reported ADR across both dose groups was eyelid ptosis, followed by neck pain, musculoskeletal stiffness.</p><p><strong>Conclusions: </strong>These real-world findings of the safety and efficacy of the 155 U - 195 U onabotulinumtoxinA doses are consistent with data from the PREEMPT clinical trials as a treatment option for CM patients.</p><p><strong>Trial registration: </strong>NCT01686581. Name of registry: ClinicalTrials.gov. URL of registry: Date of retrospective registration: September 18, 2012. Date of enrolment of first patient: July 23, 2012.</p>","PeriodicalId":9170,"journal":{"name":"BMC Neurology","volume":"25 1","pages":"197"},"PeriodicalIF":2.2,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12053858/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long term follow-up of multiorgan disease in Kleefstra syndrome 2 in an adult - case report.","authors":"Zhiyong Chen, Jia Liang Kwek, Ru Sin Lim, Yan Rong Yong, Alwin Hwai Liang Loh, Weng Khong Lim, Jing Xian Teo, Karine Su Shan Tay, Peng Soon Ng","doi":"10.1186/s12883-025-04210-8","DOIUrl":"10.1186/s12883-025-04210-8","url":null,"abstract":"<p><strong>Objectives: </strong>The Kleefstra syndrome spectrum (KSS) is a group of neurodevelopmental disorders characterized by intellectual disability, behavioral disorders, growth and neurodevelopmental delay, facial dysmorphism and neurological deficits. Kleefstra syndrome 2 (KLEFS2) is a part of KSS and is due to heterozygous loss-of-function variants in the KMT2 C gene. We report the long-term clinical course and multi-organ manifestations of a patient with KLEFS2 caused by a novel heterozygous pathogenic variant in KMT2 C.</p><p><strong>Methods: </strong>A patient with KSS phenotype developed proteinuria with progressive kidney dysfunction secondary to focal segmental glomerular sclerosis. She subsequently developed recurrent episodes that mimicked mitochondrial stroke-like episodes. The phenotype included encephalopathy, stroke-like episodes with focal status epilepticus with impaired consciousness associated with cortical and subcortical T2/FLAIR signal hyperintensities that partially responded to intravenous arginine infusions.</p><p><strong>Results: </strong>Exome sequencing revealed a heterozygous pathogenic nonsense variant in KMT2 C (NM_170606.3) c.3940C > T (p.Gln1314Ter). Nuclear and mitochondrial DNA variants associated with mitochondrial disorders have been excluded.</p><p><strong>Discussion: </strong>This is a case of KLEFS2 with longitudinal 10 year follow up and its previously unreported multi-organ clinical manifestations including stroke-like episodes and nephrotic disease. Our report further expands the phenotypic spectrum of KLEFS2. Further reports of patients with KLEFS2 with multi-organ involvement should be sought to confirm our findings.</p>","PeriodicalId":9170,"journal":{"name":"BMC Neurology","volume":"25 1","pages":"199"},"PeriodicalIF":2.2,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of low dose thyroxine in patients with subclinical hypothyroidism and migraine; systematic review and meta-analysis.","authors":"Alia Alokley, Maryam N ALNasser, Razan Anwar Alabdulqader, Faisal Abdulhamid Aljohni, Duaa Hussain Alqadhib, Rose Khalid Aljuaid, Montather Akeel Alshik Ali, Shahad Shadi Hanbazazah, Abdullah Almaqhawi","doi":"10.1186/s12883-025-04214-4","DOIUrl":"https://doi.org/10.1186/s12883-025-04214-4","url":null,"abstract":"<p><strong>Background: </strong>Subclinical hypothyroidism (SCH) is defined by elevated thyroid-stimulating hormone (TSH) levels alongside normal free thyroxine (T4) and triiodothyronine (T3) levels. Emerging evidence suggests a link between SCH and migraine disorders, including both episodic and chronic migraine. Given this association, researchers have explored whether correcting mild thyroid dysfunction with low-dose levothyroxine could alleviate migraine symptoms in affected individuals. This study investigates the potential efficacy of low-dose thyroid replacement therapy in reducing migraine frequency and severity among patients with comorbid SCH and migraine.</p><p><strong>Methods: </strong>A search was conducted on Cochrane Central, Medline, Embase, Web of Science Core Collection, and Scopus to identify randomized clinical trials (RCTs), case-control studies, and cohort research studies evaluating the use of low-dose thyroxine in patients with subclinical hypothyroidism (SCH).</p><p><strong>Results: </strong>This review analyzed four studies, two of which qualified for meta-analysis. The findings suggest a potential association between (SCH) and migraine. Notably, levothyroxine treatment in hypothyroid patients appeared to correlate with reduced migraine frequency and headache severity. However, while the meta-analysis showed a trend toward migraine reduction with thyroxine therapy, the results did not reach statistical significance - likely due to the limited study sample included in the analysis.</p><p><strong>Conclusion: </strong>The study highlights the importance of thyroid screening in migraine management, due to the link between hypothyroidism and migraines. It recommends routine thyroid function assessments for migraine patients and suggests personalized treatment approaches. Early intervention can minimize migraine episodes and improve quality of life. Adherence to low dose levothyroxine regimens can reduce migraine frequency. Further research is required to elucidate the underlying mechanisms, optimize treatment protocols, and explore potential comorbidities.</p>","PeriodicalId":9170,"journal":{"name":"BMC Neurology","volume":"25 1","pages":"198"},"PeriodicalIF":2.2,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of exoskeleton rehabilitation robot training on neuroplasticity and lower limb motor function in patients with stroke.","authors":"Tao Fan, Peng Zheng, Xue Zhang, Ze Gong, Yu Shi, Mingyang Wei, Jing Zhou, Longlong He, Shilin Li, Qing Zeng, Pengcheng Lu, Yijin Zhao, Jihua Zou, Rong Chen, Zhangqi Peng, Chenyu Xu, Peihua Cao, Guozhi Huang","doi":"10.1186/s12883-025-04203-7","DOIUrl":"10.1186/s12883-025-04203-7","url":null,"abstract":"<p><strong>Background: </strong>Lower limb exoskeleton rehabilitation robot is a new technology to improve the lower limb motor function of stroke patients. Recovery of motor function after stroke is closely related to neuroplasticity in the motor cortex and associated motor areas. However, few studies investigate how rehabilitation robots affect the neuroplasticity of stroke patients.This study sought to determine the effects of lower limb exoskeleton robot walking training on neuroplasticity and lower limb motor function in patients with stroke.</p><p><strong>Methods: </strong>A total of 25 (50.26 ± 11.42 years, 68.0% male) patients(age 18-75 years, onset between 2 weeks and 6 months) with a stable condition after having a stroke were randomized into a treatment (n = 13) and control group (n = 12). Bilateral Exoskeletal Assistive Robot H1 (BEAR-H1) walking training was provided to the treatment group, whereas conventional walking training was provided to the control group. Both groups completed two training sessions per day for 30 min each and were trained 5 days a week for 4 weeks. Transcranial magnetic stimulation, Fugl-Meyer Assessment lower extremity, Functional Ambulation Category 6-min walking distance test, intelligent gait analysis, and surface electromyography of the lower limbs were performed before and 4 weeks after treatment.</p><p><strong>Results: </strong>Both groups showed obvious improvements in all evaluation indicators (p < 0.05). Compared with the control group, the treatment group exhibited a decreased resting motor threshold and increased motor-evoked potential amplitude and recruitment curve slope (p < 0.05). The treatment group performed better than the control group (p < 0.05) in the 6-min walk test and knee flexion co-contraction ratio (CR). Correlation analysis showed that resting motor threshold, motor-evoked potential amplitude, and the recruitment curve slope were significantly correlated with the 6-min walk test, CR on ankle dorsiflexion, the root mean square of the tibialis anterior, biceps femoris, and medial gastrocnemius (p < 0.05).</p><p><strong>Conclusion: </strong>Walking training using the bilateral exoskeletal assistive robot H1 improved cerebral cortical excitability in patients with stroke, which facilitated changes in neuroplasticity and enhanced lower limb motor function.</p><p><strong>Registration: </strong>Chinese Clinical Trail Registry: ChiCTR1900028262. Registered Date: December 16,2019. Registration-URL: http://www.chictr.org.cn.</p>","PeriodicalId":9170,"journal":{"name":"BMC Neurology","volume":"25 1","pages":"193"},"PeriodicalIF":2.2,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12049012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Missed golden hours of stroke patients at Zweditu Memorial Hospital in Addis Ababa, Ethiopia.","authors":"Robel Sintayehu, Tsion Tinsae, Merahi Kefyalew","doi":"10.1186/s12883-025-04209-1","DOIUrl":"https://doi.org/10.1186/s12883-025-04209-1","url":null,"abstract":"<p><strong>Background: </strong>Seeking medical attention promptly after an acute stroke is essential for effective treatment and improved patient outcomes. However, delayed medical intervention after acute stroke contributes to increased mortality and morbidity. This study explored factors that contribute to the delayed appearance of stroke patients at the emergency department.</p><p><strong>Methods: </strong>A prospective cross-sectional study was conducted for 9 months at a referral hospital in Addis Ababa. Data was collected using questionnaires administered to stroke patients or their caregivers upon their arrival at the emergency department. Electronic medical records were further reviewed, and the treating physicians described the subsequent management of the patient after their arrival at the emergency department. Data was analyzed using descriptive and analytic parameters.</p><p><strong>Results: </strong>Only 33.3% (n = 30) arrived at the emergency department within 4.5 h. Hemorrhagic stroke was a statistically significant predictor of early presentation to the emergency department (OR = 3.182; 95% CI (1.258-8.046); p = 0.036). The absence of any substance was another marginally significant predictor for early appearance (OR = 2.555; 95% (0.936-6.970); p = 0.067). One of the marginally significant predictors for late presentation was low drug adherence (OR = 0.224; 95% CI (0.48-1.044); p = 0.057). The other factors attributed to the time of arrival, though not statistically significant, were level of education, perception of stroke as a serious illness, and prior number of health visits before arrival to the emergency department.</p><p><strong>Conclusion: </strong>The study found that many of the factors that cause delays in getting to the hospital can be changed, except for the type of stroke. Time spent in the hospital could also be positively impacted by the intervention from the appropriate authorities.</p>","PeriodicalId":9170,"journal":{"name":"BMC Neurology","volume":"25 1","pages":"194"},"PeriodicalIF":2.2,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12049002/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143953773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic radiosurgery for tumor-related trigeminal neuralgia: a systematic review and meta-analysis.","authors":"Bardia Hajikarimloo, Ibrahim Mohammadzadeh, Salem M Tos, Arman Hasanzade, Hadi Sahrai, Pourya Taghipour, Mohammadreza Amjadzadeh, Dorsa Najari, Azin Ebrahimi, Elina Roustaei, Mohammad Amin Habibi","doi":"10.1186/s12883-025-04204-6","DOIUrl":"https://doi.org/10.1186/s12883-025-04204-6","url":null,"abstract":"<p><strong>Background: </strong>Tumor-related trigeminal neuralgia (TRTN) accounts for approximately 6% of all facial pain syndromes. Conventional medical treatments have short-term pain relief effects in TRTN cases; however, they are correlated with substantial failure rates of 63-100%. Microsurgical resection (MS) and stereotactic radiosurgery (SRS) are the two primary therapeutic options for the management of TRTNs. This systematic review and meta-analysis evaluated the pain-related outcomes and complications of SRS in TRTNs.</p><p><strong>Methods: </strong>A systematic literature search was conducted on February 24, 2025, comparing PubMed, Embase, Scopus, and Web of Science. Studies reporting pain-related outcomes and adverse radiation effects (ARE) for SRS in TRTNs were included.</p><p><strong>Results: </strong>Nineteen studies with 454 patients were included. Meningioma (67.7%, 304/449) was the most common tumor, followed by vestibular schwannoma (VS) (18.3%, 82/449) and trigeminal schwannoma (8.2%, 37/449). Our meta-analysis demonstrated that SRS is associated with a pooled complete pain-free rate of 38% (95% CI: 27-50%), an adequate pain relief rate of 73% (95% CI: 63-83%), and an ARE rate of 14% (95% CI: 7-22%). In those where the underlying etiology was pertoclival meningiomas, SRS resulted in a pooled complete pain-free rate of 30% (95%CI: 5-64%), an adequate complete pain relief rate of 64% (95%CI: 33-90%), and an ARE rate of 13% (95%CI: 0-48%).</p><p><strong>Conclusion: </strong>SRS is associated with favorable pain-related outcomes and low ARE rates in patients with TRTN. Both tumor-only related and dual-targeted approaches are associated with comparable outcomes.</p>","PeriodicalId":9170,"journal":{"name":"BMC Neurology","volume":"25 1","pages":"195"},"PeriodicalIF":2.2,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12048969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between sphingomyelin levels and gut microbiota abundance in Alzheimer's disease: a two-sample Mendelian randomization study.","authors":"Liping Wang, Yuyan Ding, Yu Tang, Mengqi Yang, Zhihui Yang, Xiao Yang, Jiazeng Xia","doi":"10.1186/s12883-025-04207-3","DOIUrl":"https://doi.org/10.1186/s12883-025-04207-3","url":null,"abstract":"<p><strong>Background: </strong>Several previous observational studies have shown that abnormal sphingomyelin metabolism may be implicated in the pathogenesis of Alzheimer's disease. To determine the causal relationship between sphingolipid abundance and gut microbiota abundance at the genetic level, we conducted a Mendelian randomization (MR) investigation.</p><p><strong>Methods: </strong>We first used the TwoSampleMR and MRPRESSO packages for conducting two-sample MR studies. Second, we utilized random effect inverse variance weighting (IVW) as the principal method of analysis and used MR‒Egger, the weighted median, the simple mode and the weighted mode as supplementary methods. Finally, we performed tests for heterogeneity and horizontal pleiotropy. These analyses were also conducted to evaluate the impact of individual SNPs on the outcomes of our analysis. A Bonferroni-corrected threshold of p = 2.4e-4(0.05/211) was considered significant, and p values less than 0·05 were considered to be suggestive of an association.</p><p><strong>Results: </strong>The results showed that sphingolipid levels were suggestively associated with the abundance of 6 gut microbiota taxa. Specifically, two taxa were positively correlated with sphingolipid levels, including the family Alcaligenaceae (p = 0.006, OR 95% CI = 1.109 [1.030-1.194]) and the species Ruminococcus callidus (p = 0.034, OR 95% CI = 1.217 [1.015-1.460]). In contrast, negative correlations were observed with the abundances of 4 gut microbiota taxa, including the genus Flavonifractor (p = 0.026, OR 95% CI = 0.804 [0.663-0.974]), the genus Streptococcus (p = 0.014, OR 95% CI = 0.909 [0.842-0.981]), the species Bacteroides caccae (p = 0.037, OR 95% CI = 0.870 [0.763-0.992]), and the species Haemophilus parainfluenzae (p = 0.006, beta 95% CI = -0.269 [-0.462, -0.076]). The results presented a normal distribution, with no anomalous values, heterogeneity, or horizontal pleiotropic effects detected.</p><p><strong>Conclusions: </strong>This two-sample MR study revealed a potential causal relationship between sphingomyelin levels and gut microbiota abundance.</p>","PeriodicalId":9170,"journal":{"name":"BMC Neurology","volume":"25 1","pages":"191"},"PeriodicalIF":2.2,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12044981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurocognitive manifestation after treatment of pediatric severe anaphylaxis.","authors":"Benjamin Nti, Sheryl Allen","doi":"10.1186/s12883-025-04177-6","DOIUrl":"https://doi.org/10.1186/s12883-025-04177-6","url":null,"abstract":"<p><strong>Background: </strong>Anaphylaxis is a common, severe, and life-threatening allergic reaction that occurs rapidly after exposure to an allergen which can affect multiple systems in the body. In rare cases, it may lead to additional neurological manifestations that are poorly understood.</p><p><strong>Case presentation: </strong>We present a case of a 14-year-old boy who experienced severe anaphylaxis necessitating airway intervention and admission to critical care. While his initial presentation and treatment aligned with current standards, he subsequently developed prolonged neurological deficits, including weakness, prosopagnosia, amnesia, and loss of basic functions, during an extended recovery period.</p><p><strong>Conclusion: </strong>This rare neurological manifestation following anaphylaxis may be overlooked by many clinicians. Therefore, it is imperative to highlight this potential complication to improve the management of patients experiencing anaphylaxis.</p>","PeriodicalId":9170,"journal":{"name":"BMC Neurology","volume":"25 1","pages":"192"},"PeriodicalIF":2.2,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12044803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated high-sensitivity C-reactive protein levels are associated with intracranial arterial stenosis in elderly patients.","authors":"Mimi Li, Shufen Liu, Chunnuan Chen","doi":"10.1186/s12883-025-04208-2","DOIUrl":"https://doi.org/10.1186/s12883-025-04208-2","url":null,"abstract":"<p><strong>Background: </strong>To determine the correlation between intracranial atherosclerotic stenosis and high-sensitivity C-reactive protein (hs-CRP) levels in elderly patients with cerebral infarction.</p><p><strong>Methods: </strong>We performed a retrospective assessment of acute minor ischemic stroke patients aged over 60 at our institution from January 2021 to May 2023. A thorough computed tomography angiography (CTA) assessment was conducted for each participant. The patients were classified into four categories according to the site of stenosis in the cerebral arteries: (1) intracranial atherosclerotic stenosis (ICAS), (2) extracranial atherosclerotic stenosis (ECAS), (3) combined intracranial and extracranial atherosclerotic stenosis (IEAS), and (4) non-arterial stenosis (NOAS). Multivariate logistic regression analysis was utilized to evaluate the relationship between intracranial atherosclerotic stenosis and hs-CRP levels. The predictive efficacy of hs-CRP for intracranial arterial stenosis was assessed utilizing the Receiver Operating Characteristic (ROC) curve.</p><p><strong>Results: </strong>The research comprised 203 participants in total. Among these, 73 individuals (34.96%) were categorized as having Intracranial Stenosis Atherosclerosis (ICAS). The hs-CRP levels in the ICAS group were markedly elevated (P = 0.011), while no significant difference in hs-CRP levels was observed between the ECAS and NOAS groups (P = 0.080). Hs-CRP levels were found to be independently correlated with intracranial arterial stenosis (OR 1.136, 95% CI 1.038-1.242, P = 0.006) following multivariable analysis, as shown in Table 2. The upper quartile of hs-CRP was determined to be a statistically significant independent risk factor for intracranial stenosis (OR 3.779, 95% CI 1.519-9.402, P = 0.004). The area under the curve (AUC) for hs-CRP was calculated to be 0.632 following the analysis of the ROC curve. The ideal cutoff value for hs-CRP was established at 3.96 mg/L, accompanied by a 95% confidence interval ranging from 0.555 to 0.710 (P = 0.001). The sensitivity and specificity were 0.500 and 0.735, respectively.</p><p><strong>Conclusions: </strong>In elderly patients with acute minor ischemic stroke, elevated hs-CRP levels are significantly correlated with intracranial atherosclerosis stenosis, rather than extracranial atherosclerotic stenosis.</p>","PeriodicalId":9170,"journal":{"name":"BMC Neurology","volume":"25 1","pages":"189"},"PeriodicalIF":2.2,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042512/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}